HMO-Enhanced Rice Formula Aids Allergic Infants

HMOs Added to Rice Formula Support Growth in Allergic Infants

A clinical trial protocol published in Frontiers in Nutrition is set to investigate a major question in infant nutrition: can specialized prebiotics added to allergy-friendly formulas help infants thrive? The RIGHT-GO study, led by Hania Szajewska of the Medical University of Warsaw and Roberto Berni Canani of the University of Naples Federico II, will compare a hydrolyzed rice formula containing human milk oligosaccharides (HMOs) against a standard allergy formula.

A Plant-Based Formula Designed to Mimic Breast Milk Benefits

For infants with cow’s milk allergy (CMA) who are not breastfed, hydrolyzed formulas are the standard dietary recommendation. Hydrolyzed rice formulas (HRF) have gained popularity as a plant-based alternative with a palatable taste. The RIGHT-GO study introduces a next step: enriching such a formula with specific compounds found naturally in breast milk.

These compounds are human milk oligosaccharides (HMOs), the third-largest solid component in human milk after fat and lactose. Two key HMOs, 2’-fucosyllactose (2’FL) and lacto-N-neotetraose (LNnT), will be added at a concentration of 1.5 g/L in a 2:1 ratio. They are not probiotics (live bacteria), but prebiotics—specialized fibers that serve as food for beneficial gut microbes. By nourishing these microbes, HMOs help build a resilient gut ecosystem, which is a primary training ground for the infant’s immune system.

The Core Mechanism: Prebiotics Train the Gut and Immune System

The connection between HMOs and infant health is mechanistic and direct. Infants cannot digest HMOs themselves. Instead, these molecules pass intact to the lower gut, where they selectively promote the growth of health-supporting bacteria like Bifidobacteria. A robust Bifidobacteria population helps maintain intestinal barrier integrity, reduces inflammation, and produces metabolites that communicate with immune cells.

This process, often called the “gut-immune axis,” is critical in early life. A well-functioning gut microbiome can help modulate allergic responses and support overall immune maturation. The trial’s inclusion of HMOs in both the test rice formula and the control cow’s milk-based formula aims to provide this immune-gut support to all participants, while primarily testing whether the rice base is an adequate vehicle for growth.

Primary Goal: Demonstrating Non-Inferior Growth Over Four Months

The study’s main objective is clinical and practical: to prove that infants with CMA fed the new HRF-HMO formula grow just as well as those fed a standard extensively hydrolyzed formula (eHF-HMO). Growth will be measured by weight-for-age z-score, a statistical method comparing an infant’s weight to international growth standards.

The trial requires 104 infants across Europe to demonstrate non-inferiority with a specific margin of -0.5 standard deviation. This statistically rigorous design ensures that any difference observed would be clinically insignificant. Secondary outcomes will track other growth parameters, stool patterns, general safety, and health-related quality of life for the families. It is important to note this is a study protocol; results on efficacy and safety are anticipated but not yet available.

Choosing a Formula for a Child with Milk Allergy

For parents managing a cow’s milk allergy, this research points to a future with more evidence-based options. Currently, the choice between a rice-based or cow’s milk-based hydrolyzed formula often involves considerations of taste, cost, and dietary preferences. The addition of HMOs to both types in this trial highlights the increasing importance of gut microbiome support in all allergy formulas.

A physician diagnosis is essential, as symptoms of CMA can overlap with other conditions. Never self-diagnose or switch formulas without pediatric guidance. For broader insights on managing food allergies, our article on preventing childhood food allergies provides context. If this trial confirms both safety and non-inferior growth, it will give pediatricians and parents confidence that a plant-based, HMO-containing formula is a complete and supportive option for allergic infants.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42111853/
https://pubmed.ncbi.nlm.nih.gov/42099620/
https://pubmed.ncbi.nlm.nih.gov/42090907/